$INSY to Report First Quarter 2015 Results

Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call as follows:

Date
Thursday, May 7, 2015

Time
10:00 a.m. EDT

Toll free (U.S.) 800-741-5804

International 212-231-2900

Webcast (live and replay)
www.insysrx.com under the ‘Investor Relations’ section.

A replay of the conference call will be available for two weeks after the call’s completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International). The conference ID for the replay is 21765354. The archived webcast will be available for 30 days via the aforementioned URL.

About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The Company’s lead product candidate is Dronabinol Oral Solution, a proprietary, orally administered, liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys^® is a registered trademark of Insys Therapeutics, Inc.